Morgan Stanley raised the firm’s price target on Insulet (PODD) to $317 from $234 and keeps an Overweight rating on the shares. Insulet “had a strong 3Q print,” says the analyst, who cites “high quality growth, strong cash flow characteristics, and catalysts on the horizon” for the firm’s higher target following the company’s quarterly report.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PODD:
- Insulet price target raised to $234 from $220 at Barclays
- Early notable gainers among liquid option names on November 8th
- Insulet price target raised to $270 from $260 at BTIG
- Insulet Reports Strong Revenue Growth and Optimistic Outlook
- Insulet sees FY24 revenue growth 20%-21%
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
